Crossmark

High-dose furmonertinib combined with intraventricular chemotherapy as salvage therapy for leptomeningeal metastasis from EGFR exon 20 insertion-mutated lung cancer

Crossref DOI link: https://doi.org/10.1007/s11060-024-04716-0

Published Online: 2024-06-25

Published Print: 2024-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yu, Chuanyong

Xu, Ting

Fang, Hehui

Wang, Xiaoyue

Liu, Na

Yang, Liangfeng

Fang, Shencun
License Information

Text and Data Mining valid from 2024-06-25

Version of Record valid from 2024-06-25
More Information

Article History

Received: 21 April 2024

Accepted: 15 May 2024

First Online: 25 June 2024

Declarations

:

: The authors declare no competing interests.

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Nanjing Chest Hospital (2023-KL023-02).

: Written informed consent was obtained from all participants before enrolment.

Document is current

Any future updates will be listed below